NICE recommends Pfizer’s rimegepant for preventing episodic migraine attacks
June 2, 2023Medical Communications NHS, NICE, Neurology, Pfizer, migraine
The National Institute for Health and Care Excellence (NICE) has announced that it has recommended an oral treatment for the …
BioInvent receives Investigational New Drug approval for monoclonal antibody BI-1910
June 2, 2023Research and Development BioInvent, NSCLC, Oncology, monoclonal antibody
Swedish clinical stage biotech company BioInvent has announced that it has received Investigational New Drug (IND) approval for its monoclonal …
European Parliament shares goal to tackle antimicrobial resistance
June 2, 2023Medical Communications EU, European Parliament, Microbiology, antimicrobial resistance
The European Parliament has shared its recommendations for a “coordinated EU response to health threats posed by antimicrobial resistance,” according …
FDA approves ANDA of 20mg generic Nitisinone capsules
June 1, 2023Medical Communications Analog Pharma, Dipharma, FDA, Nitisinone, Rare Diseases
Analog Pharma and Dipharma have announced that the US Food and Drug Administration (FDA) has approved their 20mg nitisinone capsules, …
FDA approves Pfizer’s RSV vaccine for older adults
June 1, 2023Research and Development FDA, Infections and infestations, Pfizer, RSV, Vaccine
Global pharmaceutical company Pfizer has announced that the US Food and Drug Administration (FDA) has approved its respiratory syncytial virus …
Sanofi announce positive phase 2 data for MS drug frexalimab
June 1, 2023Research and Development Neurology, Sanofi, clinical trial, frexalimab, multiple sclerosis
French pharmaceutical and healthcare company Sanofi have announced positive trial data from its phase 2 clinical study into its relapsing …
Lonza to acquire Synaffix to strengthen ADC development
June 1, 2023Medical Communications ADC, Lonza, Oncology, Synaffix, drug development
Global manufacturer for the pharmaceutical, biotech and nutraceutical markets, Lonza has announced that it has acquired Synaffix, a biotech company …
Bristol Myers Squibb’s NDA accepted by FDA
May 31, 2023Medical Communications FDA, NDA, NSCLC, Oncology, bristol myers squibb
Global pharmaceutical company Bristol Myers Squibb (BMS) has announced that its New Drug Application (NDA) has been accepted by the …
SNIPR Biome reports positive findings for first-in-human, CRISPR-based microbial gene therapy
May 31, 2023Research and Development Infections and infestations, SNIPR Biome, clinical trial, crispr, gene therapy
Danish CRISPR-based microbial gene therapy company SNIPR Biome have announced positive interim data from its phase 1 clinical trial with …
Pharmanovia and Stealth BioTherapeutics enter new licensing agreement for novel Barth syndrome treatment
May 31, 2023Sales and Marketing Barth syndrome, Cardiology, Pharmanovia, Stealth BioTherapeutics, licensing agreement
Pharmanovia and Stealth BioTherapeutics have announced that they have entered into a new licensing agreement for the marketing and further …
Merck invests €35m in biosafety testing in Scotland
May 31, 2023Manufacturing and Production Merck, biosafety, drug development, testing
Merck has announced that it has invested €35m in biosafety testing at its sites in Glasgow and Stirling, both Scotland. …
Pulse Medical receives FDA BDD for its μFR system
May 30, 2023Medical Communications BDD, Cardiology, FDA, Pulse Medical
Shanghai, China-based Pulse Medical Technology has announced that its 4th generation μFR system has received Breakthrough Device Designation (BDD) from …
AstraZeneca’s Ultomiris approved in Japan for prevention of relapses in patients with NMOSD
May 30, 2023Medical Communications AstraZeneca, NMOSD, Neurology, Ultomiris
AstraZeneca has announced that Ultomiris (ravulizumab) has been approved in Japan as a long-acting C5 complement inhibitor for the prevention …
FDA approves first oral antiviral to treat adult patients with COVID-19
May 26, 2023Medical Communications COVID-19, FDA, Infections and infestations, paxlovid
The US Food and Drug Administration (FDA) has announced that it has approved the oral antiviral Paxlovid (nirmatrelvir tablets and …
Scientists use AI to find new antibiotic to fight superbug
May 26, 2023Research and Development AI, Microbiology, WHO, abaucin, antibiotic resistance
Scientists at McMaster University and the Massachusetts Institute of Technology (MIT) have utilised artificial intelligence (AI) in order to discover …
ZOLL remedē System receives FDA approval for sleep apnoea treatment
May 25, 2023Medical Communications Ear Nose & throat, FDA, ZOLL, sleep apnoea
ZOLL Medical Corporation has announced that it has received approval from the US Food and Drug Administration (FDA) for its …
BioInvent and Transgene announce positive phase 1a solid tumour trial data
May 25, 2023Research and Development BioInvent, Oncology, Transgene, clinical trials, oncology, tumours
Sweden-based BioInvent and French Transgene, both biotech companies, have reported positive phase 1a data from a trial studying BT-001 for …
ElevateBio announced $401m in Series D financing for cell and gene therapies
May 25, 2023Sales and Marketing ElevateBio, Financing, cell and gene therapies
US-based cell and gene therapy (CGT) company ElevateBio has announced that, at the end of its Series D financing led …
AstraZeneca shares oncology data at ASCO 2023
May 25, 2023Medical Communications ASCO, AstraZeneca, Cancer, Oncology, oncology
AstraZeneca plans to share data from its oncology pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting on …
Artivion receives FDA PMA approval of PerClot; transfers designation to Baxter
May 24, 2023Medical Communications Artivion, Baxter International, Cardiology, FDA, PMA, PerClot
US cardiac and vascular surgery company Artivion has announced that the US Food and Drug Administration (FDA) has granted a …
Latest content
FibroFind appoints Lee Borthwick as CEO
